Læknablaðið

Árgangur

Læknablaðið - 01.02.2015, Blaðsíða 25

Læknablaðið - 01.02.2015, Blaðsíða 25
LÆKNAblaðið 2015/101 93 Y F i R l i T 1. Murphy DL, Timpano KR, Wheaton MG, Greenberg BD, Miguel EC. Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts. Dialogues Clin Neurosci 2010; 12: 131-48. 2. Janet P. Les Obsessions et la Psychathenie. Alcan, Paris 1903. 3. Salzman L. Obsessional personality. Science House, New York 1968. 4. Hudak R (Ed.). Clinical obsessive-disorders in adults and children. 1st ed. Cambridge University Press, Cambridge 2011. 5. Burgy M. Obsession in the strict sense: A helpful psycho- pathological phenomenon in the differential diagnosis between obsessive-compulsive disorder and schizop- hrenia. Psychopathology 2007; 40: 102-10. 6. Oulis P, Konstantakopoulos G, Lykouras L, Michalopoulo. Differential diagnosis of obsessive- compulsive symptoms from delusions in schizophrenia: A phenomenological approach. World G Psychiatry 2013; 22: 50-6. 7. Heyman I, Mataix-Cols D, Fineberg NA. Obsessive- compulsive disorder, Clinical review. BMJ 2006; 333: 424-9. 8. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA. DSM-IV field trial: obsessive compulsive disorder. Am J Psychiatry 1995; 152: 90-6. 9. World health organization. International classification of diseases and related health problems, tenth revision (ICD-10). WHO, Genf 1992. 10. Hollander E. Obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997; 58(Suppl 12):3-6. 11. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK et al. The cross national epidemiology of obsessive-compulsive disorder. The cross national group. J Clin Psychiatry 1994; 55 Suppl: 5-10. 12. Ivarsson T, Melin K, Wallin K. Categorical and dimen- sional aspects of co-morbidity in obsessive-compulsive disorder. Eur Child Adolesc Psychiatry 2008; 17: 20-31. 13. American Psychiatric Association. Diagnostic and statisti- cal manual of mental disorders, Fifth Edition (DSM-V). Washington DC 2013. 14. National Institute for Health and Care Excellence. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. NICE, London 2005. 15. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemio- logy of obsessive compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53-63. 16. Murray CJ, Lopez AD. Evidence based health policy – lessons from the global burden of disease study. Science 1996; 274: 740-3. 17. Geller DA, Klier CM, Neugebauer R. Anxiety disorders following miscarriage. J Clin Psychiatry 2001; 62: 432-8. 18. Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry 1997; 58: 330-4. 19. Janowitz D, Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, et al. Early onset obsessive-compulsive disorder and associated comorbidity. Depress Anxiety 2009; 26: 1012-7. 20. Tukel R, Plolat A, Ozdemir O, Aksut D, Turksoy N. Co-morbid conditions in obsessive-compulsive disorder. Compr Psychiatry 2002; 43: 204-9. 21. Torresan RC, Ramos-Cerqueira AT, Shavitt RG, do Rosario MC, de Mathis MA, Miguel MC et al. Symptom dimensions, clinical course and comorbidity in men and women with obsessive-compulsive disorder. Psychiatry Res 2013; 30: 186-95. 22. Torres AR, Prince MJ, Bebbington BE, Brugha T, Bhugra D, Farrel M. Am J Psychiatry 2006; 163: 1978-85. 23. Maia TV, Cooney RE, Peterson BS. The neural bases of obsessive-compulsive disorder in children and adults. Dev Psychopathol 2008; 20: 1251-83. 24. Pauls DL, Abramovitch, Rauch SL, Geller DA. Obsessive- compulsive disorder: an integrative genetic and neurobio- logical perspective. Nature Rev Neurosci 2014; 15: 410-24. 25. Fitzgerald KS, Welsh RC, Stern ER, Angstadt M, Hanna GL, Abelson JL et al. Developmental alterations of frontal- striatal-thalamic connectivity in obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 938-48. 26. Baxter LR. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15: 871-84. 27. Saxena S, Brody Al, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35: 26-37. 28. Nikolaus S, Antke C, Beu M, Muller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders – results from in vivo imaging studies. Rev Neurosci 2010; 21: 119-39. 29. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al. In vivo PET study 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naïve obsessive- compulsive disorder. Neuroimage 2008; 42: 306-14. 30. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin tran- sporters in obsessive-compulsive disorder correlates with symptom severity – a (11C)DASP PET study. J Neural Trans 2007; 114: 1603-9. 31. Insel TR, Mueller TA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985; 20: 1174-88. 32. Denys D, de Vries F, Cath D, Figee M, Vulink M, Veltman DJ, et al. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2013; 23: 1423-31. 33. Nestadt G, Grados M, Samuels JF. Genetics of obsessive compulsive disorder. Psychitr Clin North Am 2010; 33: 141-58. 34. Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies in obsessive-compulsive disorder: a review. Twin Res Hum Genet 2005; 8: 450-8. 35. Rachman S. A cognitive theory of obsessions. Behav Res Ther 1997; 35: 793-802. 36. Salkovskis PM. Responsibility attitudes and interpreta- tions are characteristic of obsessive-compulsive disorder. Behav Res Ther 2000; 38: 347-72. 37. Rachman S, Hodgson R. Obsessions and compulsions. Prentice Hall, Englewood Cliffs 1980. 38. Goodman WK, Price LH, Rasmussen LA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown obsessive- compulsive scale I. Development, use and reliability. Arch Gen Psychiatry 1989; 46: 1006-11. 39. Pallanti S, Quercioli L. Treatment refractory obsess- ive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 400-12. 40. Ananth J. Treatment of obsessive-compulsive neurosis with clomipramine (anafranil). J Int Med Res 1977; 5 Suppl 5: 38-41. 41. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281-5. 42. Fineberg NA, Reghunandanan S, Brown A, Pampaloni. Pharmacotherapy of obsessive-compulsive disorder: evi- dence-based treatment and beyond. Aust N Z J Psychiatry 2013; 47: 121-41. 43. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 2014; 37: 375-91. 44. Bandelow B. The medical treatment of obsessive-compul- sive disorder and anxiety. CNS Spectr 2008; 13(Suppl 14): 37-46. 45. FDA drug safety communication: Revised recomm- endations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. fda.gov/drugs/drugsafety/ucm297391.htm - nóvember 2014. 46. McDougle CJ, Goodman WK, Price LH. The pharma- cotherapy of obsessive-compulsive disorder. Pharmacopsychiatry 1993; 26 (Suppl 1): 24-9. 47. Goddard A, Shin YW. Augmentation of serotonin reup- take inhibitors in the treatment of obsessive-compulsive disorder. In: Hudak R, Dougherty DD (Eds.). Clinical obsessive-disorders in adults and children. 1st ed. Cambridge University Press, Cambridge 2011: 49-60. 48. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8: 61-7. 49. Matsunaga H, Kiriike N, Matsui T, Oya K, Iwasaki Y. Obsessive-compulsive disorder with poor insight. Compr Psychiatry 2002; 43: 150-7. 50. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antip- sychotics. J Manag Care Pharm 2012; 18(5 SupplB): 1-20. 51. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010; 12: 187-97. 52. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 151-61. 53. Franklin ME, Abramowitz JS, Kozak MJ, Levitt JT, Foa EB. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000; 68: 594-602. 54. Marks I. Exposure therapy for phobias and obsessive- compulsive disorders. Hosp Pract 1979; 14: 101-8. 55. Mancebo MC, Eisen JL, Sibrava NJ, Dyck IR, Rasmussen RA. Patient utilization of cognitive-behavioral therapy for OCD. Behav Ther 2011; 42: 399-412. 56. Sighvatsson MB, Kristjansdottir H, Sigurdsson E, Sigurdsson JF. Gagnsemi hugrænnar atferlismeðferðar við lyndis- og kvíðaröskunum hjá fullorðnum. Læknablaðið 2011; 97: 613-9. 57. Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP et al. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry 2013; 74: 464-9. 58. Abramowitz JS, Storch EA, Keeley M, Cordell E. Obsessive-compulsive disorder with comorbid major depression: what is the role of cognitive factors? Behav Res Ther 2007; 45: 2257-67. 59. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Niremberg AA. Prospective long-term follow-up of 44 patients who received cingulectomy for obsessive- compulsive disorder. Am J Psychiatry 2002; 159: 269-75. 60. Greenberg BD, Rauch SL, Haber SN. Invasive circuitry- based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 2010; 35: 317-36. 61. Jakubovski E, Diniz JB, Valerio C, Fossaluza V, Belotto- Silva C, Gorenstein C, et al. Clinical predictors of long- term outcome in obsessive-compulsive disorder. Depress Anxiety 2013; 30: 763-7. 62. Abramowitz JS, Lackey GR, Wheaton MG. Obsessive- compulsive symptoms: the contribution of experimental beliefs and experiential avoidance. J Anxiety Disord 2009; 23: 160-6. 63. Glazier K, Calixte RM, Rothschild R, Pinto A. High rates of OCD symptom misidentification by mental health professionals. Ann Clin Psychiatry 2013; 25: 201-9. Heimildir

x

Læknablaðið

Beinir tenglar

Ef þú vilt tengja á þennan titil, vinsamlegast notaðu þessa tengla:

Tengja á þennan titil: Læknablaðið
https://timarit.is/publication/986

Tengja á þetta tölublað:

Tengja á þessa síðu:

Tengja á þessa grein:

Vinsamlegast ekki tengja beint á myndir eða PDF skjöl á Tímarit.is þar sem slíkar slóðir geta breyst án fyrirvara. Notið slóðirnar hér fyrir ofan til að tengja á vefinn.